Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
Biohaven registers Phase 2b/3 study of BHV-1300 in Graves' Disease
The study, led by Biohaven Therapeutics Ltd., plans to enroll an estimate of 356 participants to evaluate the safety and tolerability of BHV-1300 in adults with Graves' Disease. It plans to start in October 2026 and reach primary completion in December 2028.
-
Phase 3 results posted, week of October 26, 2026: 9 industry trials
Industry sponsors posted results for 9 Phase 3 trials on ClinicalTrials.gov in the week of October 26 to November 1, 2026. Together the trials enrolled 4,377 participants; the largest, Hoffmann-La Roche's ARNASA trial, enrolled 1,380.
-
Precigen registers Phase 3 study of zopapogene imadenovec in pediatric RRP
The study, led by Precigen, Inc., plans to enroll 15 participants and has a planned start date of December 31, 2026, with a planned primary completion date of January 2029. It plans to assess the safety and efficacy of zopapogene imadenovec, an investigational immunotherapy, in children with recurrent respiratory papillomatosis.
-
Hoffmann-La Roche posts results of Phase III astegolimab trial in COPD
The study enrolled 1380 participants and completed primary data collection on June 24, 2025. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
DBV Technologies posts results of Phase 3 DBV712 study in peanut-allergic children
The study, completed with 304 participants, posted results on ClinicalTrials.gov on October 28, 2026. It was an open-label extension of the EPITOPE study evaluating long-term clinical benefit and safety of DBV712 in peanut-allergic children.
-
Bausch Health posts results of Phase 3 rifaximin SSD study in cirrhosis
The study, completed in February 2026, enrolled 517 participants and evaluated rifaximin SSD-40mg IR for delaying the first episode of overt hepatic encephalopathy in patients with liver cirrhosis. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
Amgen posts results of Phase 3 erenumab trial in pediatric chronic migraine
The study, completed with 284 participants, evaluated erenumab in children 6 to <12 years and adolescents 12 to <18 years with chronic migraine. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
Apellis posts results of Phase 3 extension study of pegcetacoplan in geographic atrophy
The study enrolled 792 participants and completed primary data collection on September 5, 2025. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
Izalontamab brengitecan versus platinum chemotherapy in EGFR-mutated NSCLC
In a phase 3 trial in China, 432 participants with EGFR-mutated advanced non-squamous NSCLC received either izalontamab brengitecan or platinum-based chemotherapy. Median BICR-assessed progression-free survival was 11·1 months with izalontamab brengitecan versus 5·7 months with chemotherapy (HR 0·40, 95% CI 0·31-0·51).
-
Rudin et al. Report extended follow-up of tarlatamab in SCLC
The authors reported that median overall survival was 13.6 months with tarlatamab versus 8.4 months with chemotherapy, with 12-month OS rates of 55.9% versus 39.0%. Grade ≥3 treatment-related adverse events decreased over time, with no serious events after 12 months.
-
AbbVie submits BLA for etentamig to FDA for relapsed/refractory multiple myeloma
AbbVie announced the submission of a Biologics License Application for etentamig, a second-generation BCMA x CD3 bispecific antibody, to the U.S. FDA for adults with relapsed or refractory multiple myeloma. The company cited Phase 3 CERVINO study results showing a 74.0% overall response rate versus 45.7% for investigator's choice and a 60% risk reduction in progression-free survival.
-
Hanmi registers Phase 3 trial of HIP2602 in erectile dysfunction
The study, led by Hanmi Pharmaceutical Company Limited, plans to enroll 225 participants and begin in October 2026. It is a multicenter, randomized, double-blind Phase III trial evaluating the efficacy and safety of HIP2602 in erectile dysfunction patients.